+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Forecast to 2028

  • PDF Icon

    Report

  • 231 Pages
  • September 2023
  • Region: Global
  • Markets and Markets
  • ID: 3758179

Increasing Collaborations and Partnerships Among Market Players for Adjuvanted Vaccine Development

The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.

The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market

Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.

infectious disease segment accounted for the largest share of the disease type segment in 2022

Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.

Asia Pacific region is likely to grow at a faster pace

The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia-Pacific - 20%, Latin America - 10%, and Middle East and Africa - 5%

List of Companies Profiled in the Report:

  • Dynavax Technologies (US)
  • Croda International plc (UK)
  • GSK plc (UK)
  • Seppic (France)
  • Novavax (US)
  • SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
  • Agenus Inc. (US)
  • Phibro Animal Health Corporation (US)
  • Aurorium (Vertellus) (US)
  • Merck KGaA (Germany)
  • Vaxine Pty Ltd. (Australia)
  • Hawaii Biotech Inc. (US)
  • CSL Limited (Australia)
  • OZ Biosciences (US)
  • InvivoGen (US)
  • Allergy Therapeutics (UK)
  • EuBiologics Co., Ltd. (South Korea)
  • Pacific GeneTech Limited (US)
  • Riboxx GmbH (Germany)
  • CaPtivate Pharmaceuticals LLC (US)
  • Creative Diagnostics (US)
  • LiteVax BV (Netherlands)
  • Mukta Industries (India)
  • Oncovir, Inc. (US)
  • TiterMax USA, Inc. (US).

Research Coverage:

This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising prevalence of infectious diseases, increasing collaborations and partnerships among market players for adjuvanted vaccines development, Growing product pipeline, Growing focus on immunization programs), restraints ( Side effects and high toxicity of adjuvants), opportunities (Growing funding for vaccines and increasing infectious disease research activities, development of plant-based vaccine adjuvants) and challenges (Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing) are influencing the growth of vaccine adjuvants market.
  • Product Development/Innovation: Detailed insights on newly launched products of the vaccine adjuvants market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the vaccine adjuvants market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccine adjuvants market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France) , Novavax (US), SPI pharma (US), Agenus Inc. (US), Phibro Animal Health Corporation (US) and among others in the vaccine adjuvants market.
Frequently Asked Questions about the Global Vaccine Adjuvants Market

What is the estimated value of the Global Vaccine Adjuvants Market?

The Global Vaccine Adjuvants Market was estimated to be valued at $0.8 Billion in 2023.

What is the growth rate of the Global Vaccine Adjuvants Market?

The growth rate of the Global Vaccine Adjuvants Market is 6.9%, with an estimated value of $1.2 Billion by 2028.

What is the forecasted size of the Global Vaccine Adjuvants Market?

The Global Vaccine Adjuvants Market is estimated to be worth $1.2 Billion by 2028.

Who are the key companies in the Global Vaccine Adjuvants Market?

Key companies in the Global Vaccine Adjuvants Market include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France), Novavax (US), SPI pharma ( subsidiary of Associated British Foods plc ) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US) and Merck KGaA (Germany).

Table of Contents

1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.2.1 Inclusions & Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered
1.3.3 Currency Considered
1.4 Research Limitations
1.5 Stakeholders
1.6 Summary of Changes
1.7 Recession Impact

2 Research Methodology
2.1 Research Approach
Figure 1 Research Design
2.1.1 Primary Research
Figure 2 Vaccine Adjuvants Market: Primary Respondents
2.1.2 Secondary Data
2.2 Market Size Estimation
Figure 3 Vaccine Adjuvants Industry Size Estimation (Supply-Side Analysis), 2022
Figure 4 Market Size Estimation: Approach 1 (Company Revenue Analysis-Based Estimation), 2022
2.2.1 Insights from Primaries
Figure 5 Market Size Validation from Primary Experts
2.2.2 Segment Assessment (By Product, Route of Administration, Disease Type, Application, Type, and Region)
Figure 6 Market Size Estimation Methodology: Top-Down Approach
2.3 Growth Rate Assumptions
Figure 7 Market (Demand Side): Growth Analysis of Demand-Side Factors
Figure 8 Market: Growth Analysis of Drivers, Restraints, Challenges, and Opportunities
2.4 Market Breakdown and Data Triangulation
Figure 9 Data Triangulation Methodology
2.5 Study Assumptions
2.6 Risk Analysis
2.7 Recession Impact Analysis
Table 1 Global Inflation Rate Projections, 2021-2027 (% Growth)

3 Executive Summary
Figure 10 Vaccine Adjuvants Market, by Product, 2023 Vs. 2028 (USD Million)
Figure 11 Market, by Route of Administration, 2023 Vs. 2028 (USD Million)
Figure 12 Market, by Disease Type, 2023 Vs. 2028 (USD Million)
Figure 13 Market, by Application, 2023 Vs. 2028 (USD Million)
Figure 14 Market, by Type, 2023 Vs. 2028 (USD Million)
Figure 15 Geographical Snapshot of Vaccine Adjuvants Industry

4 Premium Insights
4.1 Vaccine Adjuvants Market Overview
Figure 16 Rising Prevalence of Infectious Diseases to Drive Market Growth
4.2 North America: Market, by Product and Country (2022)
Figure 17 Adjuvant Emulsions Accounted for Largest Share of North American Market in 2022
4.3 Market Share, by Product, 2023 Vs. 2028
Figure 18 Adjuvant Emulsions Segment to Continue to Dominate Market in 2028
4.4 Market: Geographic Growth Opportunities
Figure 19 Asia-Pacific Countries to Register Highest Growth Rates from 2023 to 2028

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 20 Vaccine Adjuvants Market: Drivers, Restraints, Opportunities, and Challenges
Table 2 Market: Impact Analysis
5.2.1 Drivers
5.2.1.1 Rising Prevalence of Infectious Diseases
5.2.1.2 Increasing Collaborations and Partnerships Among Market Players for Adjuvanted Vaccine Development
5.2.1.3 Growing Product Pipeline
Figure 21 Pipeline of Vaccine Adjuvants
5.2.1.4 Growing Focus on Immunization Programs
5.2.2 Restraints
5.2.2.1 Side Effects and Toxicity of Adjuvants
5.2.3 Opportunities
5.2.3.1 Growing Funding for Vaccines and Increasing Infectious Disease Research Activities
Table 3 Nih Funding for Vaccine Research, 2019-2023 (USD Million)
5.2.3.2 Development of Plant-Based Vaccine Adjuvants
5.2.4 Challenges
5.2.4.1 Concerns Regarding Animal-Sourced Vaccine Adjuvants and Shark Fishing
5.3 Trends/Disruptions Impacting Customers’ Businesses
Figure 22 Revenue Shift and New Revenue Pockets for Vaccine Adjuvant Providers
5.4 Pricing Analysis
5.4.1 Average Selling Price of Products Offered by Key Players
Table 4 Average Selling Price of Products Offered by Key Players (Top 5)
5.4.2 Average Selling Price, by Product Type
Table 5 Average Selling Price of Adjuvant Emulsions
Table 6 Average Selling Price of Particulate Adjuvants
Table 7 Average Selling Price of Saponin-Based Adjuvants
5.5 Technology Analysis
5.6 Value Chain Analysis
Figure 23 Value Chain Analysis: Raw Material and Manufacturing Phases Contribute Maximum Value
5.7 Ecosystem Analysis
Figure 24 Ecosystem Analysis
Table 8 Supply Chain Ecosystem
5.8 Key Conferences & Events in 2023-2024
Table 9 Market: Detailed List of Conferences and Events
5.9 Regulatory Analysis
5.9.1 Regulatory Landscape for Vaccine Adjuvants
5.9.2 Regulatory Bodies, Government Agencies, and Other Organizations
Table 10 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 11 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 12 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 13 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 14 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
5.10 Porter's Five Forces Analysis
Table 15 Market: Porter's Five Forces Analysis
5.10.1 Threat of New Entrants
5.10.2 Threat of Substitutes
5.10.3 Bargaining Power of Suppliers
5.10.4 Bargaining Power of Buyers
5.10.5 Degree of Competition
Figure 25 Patent Applications for Vaccine Adjuvants, August 2013-August 2023
Table 16 Market: Indicative List of Patents
5.11 Key Stakeholders & Buying Criteria
5.11.1 Key Stakeholders in Buying Process
Figure 26 Influence of Stakeholders on Buying Process of Vaccine Adjuvants
5.11.2 Buying Criteria for Vaccine Adjuvant Products
Figure 27 Key Buying Criteria for End-users

6 Vaccine Adjuvants Market, by Product
6.1 Introduction
Table 17 Vaccine Adjuvants Industry, by Product, 2021-2028 (USD Million)
6.2 Adjuvant Emulsions
6.2.1 Extensive Use of Adjuvant Emulsions in Human Vaccines to Drive Growth
Table 18 Adjuvant Emulsions Market, by Region, 2021-2028 (USD Million)
Table 19 North America: Adjuvant Emulsions Market, by Country, 2021-2028 (USD Million)
Table 20 Europe: Adjuvant Emulsions Market, by Country, 2021-2028 (USD Million)
Table 21 Asia-Pacific: Adjuvant Emulsions Market, by Country, 2021-2028 (USD Million)
6.3 Pathogen Components
6.3.1 Increasing Number of Prominent Players Offering Bacteria-Derived Adjuvants to Drive Growth
Table 22 Pathogen Components Market, by Region, 2021-2028 (USD Million)
Table 23 North America: Pathogen Components Market, by Country, 2021-2028 (USD Million)
Table 24 Europe: Pathogen Components Market, by Country, 2021-2028 (USD Million)
Table 25 Asia-Pacific: Pathogen Components Market, by Country, 2021-2028 (USD Million)
6.4 Saponin-Based Adjuvants
6.4.1 Increasing Use of Saponin-Based Adjuvants to Support Market Growth
Table 26 Saponin-Based Adjuvants Market, by Region, 2021-2028 (USD Million)
Table 27 North America: Saponin-Based Adjuvants Market, by Country, 2021-2028 (USD Million)
Table 28 Europe: Saponin-Based Adjuvants Market, by Country, 2021-2028 (USD Million)
Table 29 Asia-Pacific: Saponin-Based Adjuvants Market, by Country, 2021-2028 (USD Million)
6.5 Particulate Adjuvants
6.5.1 Growing Demand for Mineral-Based Adjuvants to Boost Market
Table 30 Particulate Adjuvants Market, by Region, 2021-2028 (USD Million)
Table 31 North America: Particulate Adjuvants Market, by Country, 2021-2028 (USD Million)
Table 32 Europe: Particulate Adjuvants Market, by Country, 2021-2028 (USD Million)
Table 33 Asia-Pacific: Particulate Adjuvants Market, by Country, 2021-2028 (USD Million)
6.6 Other Adjuvants
Table 34 Other Market, by Region, 2021-2028 (USD Million)
Table 35 North America: Other Market, by Country, 2021-2028 (USD Million)
Table 36 Europe: Other Market, by Country, 2021-2028 (USD Million)
Table 37 Asia-Pacific: Other Market, by Country, 2021-2028 (USD Million)

7 Vaccine Adjuvants Market, by Route of Administration
7.1 Introduction
Table 38 Vaccine Adjuvants Industry, by Route of Administration, 2021-2028 (USD Million)
7.2 Intramuscular
7.2.1 Better Absorption Rate Associated with Intramuscular Administration to Drive Market Growth
Table 39 Advantages and Disadvantages of Intramuscular Administration
Table 40 Market for Intramuscular Administration, by Region, 2021-2028 (USD Million)
Table 41 North America: Market for Intramuscular Administration, by Country, 2021-2028 (USD Million)
Table 42 Europe: Market for Intramuscular Administration, by Country, 2021-2028 (USD Million)
Table 43 Asia-Pacific: Market for Intramuscular Administration, by Country, 2021-2028 (USD Million)
7.3 Subcutaneous
7.3.1 Frequent Use of Subcutaneous Route of Administration to Boost Market
Table 44 Advantages and Disadvantages of Subcutaneous Administration
Table 45 Market for Subcutaneous Administration, by Region, 2021-2028 (USD Million)
Table 46 North America: Market for Subcutaneous Administration, by Country, 2021-2028 (USD Million)
Table 47 Europe: Market for Subcutaneous Administration, by Country, 2021-2028 (USD Million)
Table 48 Asia-Pacific: Market for Subcutaneous Administration, by Country, 2021-2028 (USD Million)
7.4 Other Routes of Administration
Table 49 Market for Other Routes of Administration, by Region, 2021-2028 (USD Million)
Table 50 North America: Market for Other Routes of Administration, by Country, 2021-2028 (USD Million)
Table 51 Europe: Market for Other Routes of Administration, by Country, 2021-2028 (USD Million)
Table 52 Asia-Pacific: Market for Other Routes of Administration, by Country, 2021-2028 (USD Million)

8 Vaccine Adjuvants Market, by Disease Type
8.1 Introduction
Table 53 Vaccine Adjuvants Industry, by Disease Type, 2021-2028 (USD Million)
8.2 Infectious Diseases
8.2.1 Growing Prevalence of Infectious Diseases to Drive Market
Table 54 Market for Infectious Diseases, by Region, 2021-2028 (USD Million)
Table 55 North America: Market for Infectious Diseases, by Country, 2021-2028 (USD Million)
Table 56 Europe: Market for Infectious Diseases, by Country, 2021-2028 (USD Million)
Table 57 Asia-Pacific: Market for Infectious Diseases, by Country, 2021-2028 (USD Million)
8.3 Cancer
8.3.1 Increasing Demand for Novel Cancer Vaccines to Support Market Growth
Table 58 Market for Cancer, by Region, 2021-2028 (USD Million)
Table 59 North America: Market for Cancer, by Country, 2021-2028 (USD Million)
Table 60 Europe: Market for Cancer, by Country, 2021-2028 (USD Million)
Table 61 Asia-Pacific: Market for Cancer, by Country, 2021-2028 (USD Million)
8.4 Other Diseases
Table 62 Market for Other Diseases, by Region, 2021-2028 (USD Million)
Table 63 North America: Market for Other Diseases, by Country, 2021-2028 (USD Million)
Table 64 Europe: Market for Other Diseases, by Country, 2021-2028 (USD Million)
Table 65 Asia-Pacific: Market for Other Diseases, by Country, 2021-2028 (USD Million)

9 Vaccine Adjuvants Market, by Application
9.1 Introduction
Table 66 Vaccine Adjuvants Industry, by Application, 2021-2028 (USD Million)
9.2 Research Applications
9.2.1 Extensive R&D for Development of Vaccine Adjuvants to Drive Market
Table 67 Market for Research Applications, by Region, 2021-2028 (USD Million)
Table 68 North America: Market for Research Applications, by Country, 2021-2028 (USD Million)
Table 69 Europe: Market for Research Applications, by Country, 2021-2028 (USD Million)
Table 70 Asia-Pacific: Market for Research Applications, by Country, 2021-2028 (USD Million)
9.3 Commercial Applications
9.3.1 Growing Use of Vaccine Adjuvants for Commercial Applications to Support Market Growth
Table 71 Market for Commercial Applications, by Region, 2021-2028 (USD Million)
Table 72 North America: Market for Commercial Applications, by Country, 2021-2028 (USD Million)
Table 73 Europe: Market for Commercial Applications, by Country, 2021-2028 (USD Million)
Table 74 Asia-Pacific: Market for Commercial Applications, by Country, 2021-2028 (USD Million)

10 Vaccine Adjuvants Market, by Type
10.1 Introduction
Table 75 Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
10.2 Human Vaccine Adjuvants
10.2.1 Increasing Partnerships for Development of Human Vaccine Adjuvants to Aid Market Growth
Table 76 Market, by Region, 2021-2028 (USD Million)
Table 77 North America: Market, by Country, 2021-2028 (USD Million)
Table 78 Europe: Market, by Country, 2021-2028 (USD Million)
Table 79 Asia-Pacific: Market, by Country, 2021-2028 (USD Million)
10.3 Veterinary Vaccine Adjuvants
10.3.1 Increasing Use of Adjuvanted Vaccines as Preventive Care in Animal Health to Drive Market
Table 80 Market, by Region, 2021-2028 (USD Million)
Table 81 North America: Market, by Country, 2021-2028 (USD Million)
Table 82 Europe: Market, by Country, 2021-2028 (USD Million)
Table 83 Asia-Pacific: Market, by Country, 2021-2028 (USD Million)

11 Vaccine Adjuvants Market, by Region
11.1 Introduction
Table 84 Vaccine Adjuvants Industry, by Region, 2021-2028 (USD Million)
11.2 North America
Figure 28 North America: Vaccine Adjuvants Market Snapshot
Table 85 North America: Market, by Country, 2021-2028 (USD Million)
Table 86 North America: Market, by Product, 2021-2028 (USD Million)
Table 87 North America: Market, by Route of Administration, 2021-2028 (USD Million)
Table 88 North America: Market, by Disease Type, 2021-2028 (USD Million)
Table 89 North America: Market, by Application, 2021-2028 (USD Million)
Table 90 North America: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.2.1 US
11.2.1.1 Us to Dominate North American Market During Forecast Period
Table 91 US: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 92 US: Market, by Route of Administration, 2021-2028 (USD Million)
Table 93 US: Market, by Disease Type, 2021-2028 (USD Million)
Table 94 US: Market, by Application, 2021-2028 (USD Million)
Table 95 US: Market, by Type, 2021-2028 (USD Million)
11.2.2 Canada
11.2.2.1 Increasing Government Funding for Vaccine Research to Drive Market Growth in Canada
Table 96 Canada: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 97 Canada: Market, by Route of Administration, 2021-2028 (USD Million)
Table 98 Canada: Market, by Disease Type, 2021-2028 (USD Million)
Table 99 Canada: Market, by Application, 2021-2028 (USD Million)
Table 100 Canada: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.2.3 North America: Recession Impact
11.3 Europe
Table 101 Europe: Vaccine Adjuvants Market, by Country, 2021-2028 (USD Million)
Table 102 Europe: Market, by Product, 2021-2028 (USD Million)
Table 103 Europe: Market, by Route of Administration, 2021-2028 (USD Million)
Table 104 Europe: Market, by Disease Type, 2021-2028 (USD Million)
Table 105 Europe: Market, by Application, 2021-2028 (USD Million)
Table 106 Europe: Market, by Type, 2021-2028 (USD Million)
11.3.1 Germany
11.3.1.1 Increasing Investments by Various Key Players to Drive Market
Table 107 Germany: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 108 Germany: Market, by Route of Administration, 2021-2028 (USD Million)
Table 109 Germany: Market, by Disease Type, 2021-2028 (USD Million)
Table 110 Germany: Market, by Application, 2021-2028 (USD Million)
Table 111 Germany: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.3.2 UK
11.3.2.1 Rising Investments in Vaccine Development to Boost Market Growth
Table 112 UK: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 113 UK: Market, by Route of Administration, 2021-2028 (USD Million)
Table 114 UK: Market, by Disease Type, 2021-2028 (USD Million)
Table 115 UK: Market, by Application, 2021-2028 (USD Million)
Table 116 UK: Market, by Type, 2021-2028 (USD Million)
11.3.3 France
11.3.3.1 Growing Focus on New Vaccine Development to Drive Market Growth
Table 117 France: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 118 France: Market, by Route of Administration, 2021-2028 (USD Million)
Table 119 France: Market, by Disease Type, 2021-2028 (USD Million)
Table 120 France: Market, by Application, 2021-2028 (USD Million)
Table 121 France: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.3.4 Italy
11.3.4.1 Growth in Life Science Research to Boost Market
Table 122 Italy: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 123 Italy: Market, by Route of Administration, 2021-2028 (USD Million)
Table 124 Italy: Market, by Disease Type, 2021-2028 (USD Million)
Table 125 Italy: Market, by Application, 2021-2028 (USD Million)
Table 126 Italy: Market, by Type, 2021-2028 (USD Million)
11.3.5 Spain
11.3.5.1 Increasing Investments in Vaccine Development by Government and Private Organizations to Support Market
Table 127 Spain: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 128 Spain: Market, by Route of Administration, 2021-2028 (USD Million)
Table 129 Spain: Market, by Disease Type, 2021-2028 (USD Million)
Table 130 Spain: Market, by Application, 2021-2028 (USD Million)
Table 131 Spain: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.3.6 Rest of Europe
Table 132 Rest of Europe: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 133 Rest of Europe: Market, by Route of Administration, 2021-2028 (USD Million)
Table 134 Rest of Europe: Market, by Disease Type, 2021-2028 (USD Million)
Table 135 Rest of Europe: Market, by Application, 2021-2028 (USD Million)
Table 136 Rest of Europe: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.3.7 Europe: Recession Impact
11.4 Asia-Pacific
Figure 29 Asia-Pacific: Vaccine Adjuvants Market Snapshot
Table 137 Asia-Pacific: Market, by Country, 2021-2028 (USD Million)
Table 138 Asia-Pacific: Market, by Product, 2021-2028 (USD Million)
Table 139 Asia-Pacific: Market, by Route of Administration, 2021-2028 (USD Million)
Table 140 Asia-Pacific: Market, by Disease Type, 2021-2028 (USD Million)
Table 141 Asia-Pacific: Market, by Application, 2021-2028 (USD Million)
Table 142 Asia-Pacific: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.4.1 China
11.4.1.1 Government Support & Strategic Initiatives by Key Players to Strengthen Biotechnology Sector in China
Table 143 China: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 144 China: Market, by Route of Administration, 2021-2028 (USD Million)
Table 145 China: Market, by Disease Type, 2021-2028 (USD Million)
Table 146 China: Market, by Application, 2021-2028 (USD Million)
Table 147 China: Market, by Type, 2021-2028 (USD Million)
11.4.2 Japan
11.4.2.1 Government Initiatives to Boost Market
Table 148 Japan: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 149 Japan: Market, by Route of Administration, 2021-2028 (USD Million)
Table 150 Japan: Market, by Disease Type, 2021-2028 (USD Million)
Table 151 Japan: Market, by Application, 2021-2028 (USD Million)
Table 152 Japan: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.4.3 India
11.4.3.1 Growth of Biotechnology Sector to Support Market
Table 153 India: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 154 India: Market, by Route of Administration, 2021-2028 (USD Million)
Table 155 India: Market, by Disease Type, 2021-2028 (USD Million)
Table 156 India: Market, by Application, 2021-2028 (USD Million)
Table 157 India: Market, by Type, 2021-2028 (USD Million)
11.4.4 Rest of Asia-Pacific
Table 158 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 159 Rest of Asia-Pacific: Market, by Route of Administration, 2021-2028 (USD Million)
Table 160 Rest of Asia-Pacific: Market, by Disease Type, 2021-2028 (USD Million)
Table 161 Rest of Asia-Pacific: Market, by Application, 2021-2028 (USD Million)
Table 162 Rest of Asia-Pacific: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)
11.4.5 Asia-Pacific: Recession Impact
11.5 Latin America
11.5.1 Growing Pharmaceutical & Biotechnology Research to Drive Market Growth
11.5.2 Latin America: Recession Impact
Table 163 Latin America: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 164 Latin America: Market, by Route of Administration, 2021-2028 (USD Million)
Table 165 Latin America: Market, by Disease Type, 2021-2028 (USD Million)
Table 166 Latin America: Market, by Application, 2021-2028 (USD Million)
Table 167 Latin America: Market, by Type, 2021-2028 (USD Million)
11.6 Middle East & Africa
11.6.1 Increasing Funding and Grants for Vaccine Development to Support Market Growth
11.6.2 Middle East & Africa: Recession Impact
Table 168 Middle East & Africa: Vaccine Adjuvants Market, by Product, 2021-2028 (USD Million)
Table 169 Middle East & Africa: Market, by Route of Administration, 2021-2028 (USD Million)
Table 170 Middle East & Africa: Market, by Disease Type, 2021-2028 (USD Million)
Table 171 Middle East & Africa: Market, by Application, 2021-2028 (USD Million)
Table 172 Middle East & Africa: Vaccine Adjuvants Industry, by Type, 2021-2028 (USD Million)

12 Competitive Landscape
12.1 Introduction
12.2 Strategies Adopted by Key Players
Figure 30 Vaccine Adjuvants Market: Strategies Adopted by Key Players
12.3 Revenue Share Analysis
Figure 31 Revenue Analysis of Key Players, 2020-2022
12.4 Market Share Analysis
Figure 32 Vaccine Adjuvants Industry: Market Share Analysis of Key Players (2022)
Table 173 Vaccine Adjuvants Industry: Degree of Competition
12.5 Company Evaluation Matrix
12.5.1 Stars
12.5.2 Emerging Leaders
12.5.3 Pervasive Players
12.5.4 Participants
Figure 33 Market: Company Evaluation Matrix for Key Players, 2022
12.5.5 Company Footprint
12.5.5.1 Product Footprint of Top 25 Companies
Table 174 Market: Company Product Footprint Analysis of Key Players
12.5.6 Regional Footprint of Top 25 Companies
Table 175 Market: Regional Footprint Analysis of Key Players
12.6 Start-Up/Sme Evaluation Matrix
12.6.1 Progressive Companies
12.6.2 Starting Blocks
12.6.3 Responsive Companies
12.6.4 Dynamic Companies
Figure 34 Market: Company Evaluation Matrix for Start-Ups/Smes, 2022
12.7 Competitive Benchmarking of Start-Up/Sme Players
Table 176 Product Footprint Analysis of Key Players in Market
Table 177 Market: Competitive Benchmarking of Start-Ups/Sme Players
12.8 Competitive Scenario and Trends
12.8.1 Product Launches & Approvals
Table 178 Market: Product Launches & Approvals, January 2021-July 2023
12.8.2 Deals
Table 179 Market: Deals, January 2021-July 2023
12.8.3 Other Developments
Table 180 Vaccine Adjuvants Market: Other Developments, January 2021-July 2023

13 Company Profiles
(Business Overview, Products Offered, Recent Developments & Analyst's View)*
13.1 Key Market Players
13.1.1 Dynavax Technologies
Table 181 Dynavax Technologies: Business Overview
Figure 35 Dynavax Technologies: Company Snapshot (2022)
13.1.2 Croda International plc
Table 182 Croda International plc: Business Overview
Figure 36 Croda International plc: Company Snapshot (2022)
13.1.3 Gsk plc
Table 183 Gsk plc: Business Overview
Figure 37 Gsk plc: Company Snapshot (2022)
13.1.4 Seppic (A Subsidiary of Air Liquide Group)
Table 184 Seppic (A Subsidiary of Air Liquide Group): Business Overview
Figure 38 Seppic (A Subsidiary of Air Liquide Group): Company Snapshot (2022)
13.1.5 Novavax
Table 185 Novavax: Business Overview
Figure 39 Novavax: Company Snapshot (2022)
13.1.6 Spi Pharma (A Subsidiary of Associated British Foods plc)
Table 186 Spi Pharma (A Subsidiary of Associated British Foods plc): Business Overview
Figure 40 Spi Pharma (A Subsidiary of Associated British Foods plc): Company Snapshot (2022)
13.1.7 Agenus Inc.
Table 187 Agenus Inc.: Business Overview
Figure 41 Agenus Inc.: Company Snapshot (2022)
13.1.8 Phibro Animal Health Corporation
Table 188 Phibro Animal Health Corporation: Business Overview
Figure 42 Phibro Animal Health Corporation: Company Snapshot (2022)
13.1.9 Aurorium (Formerly Vertellus)
Table 189 Aurorium (Formerly Vertellus): Business Overview
13.1.10 Merck KGaA
Table 190 Merck KGaA: Business Overview
Figure 43 Merck KGaA: Company Snapshot (2022)
13.1.11 Vaxine Pty Ltd.
Table 191 Vaxine Pty Ltd.: Business Overview
13.1.12 Hawaii Biotech Inc.
Table 192 Hawaii Biotech Inc.: Business Overview
13.1.13 Csl Limited
Table 193 Csl Limited: Business Overview
Figure 44 Csl Limited: Company Snapshot (2022)
13.1.14 Oz Biosciences
Table 194 Oz Biosciences: Business Overview
13.1.15 Invivogen
Table 195 Invivogen: Business Overview
13.1.16 Allergy Therapeutics
Table 196 Allergy Therapeutics: Business Overview
Figure 45 Allergy Therapeutics: Company Snapshot (2022)
13.1.17 Eubiologics Co., Ltd.
Table 197 Eubiologics Co., Ltd.: Business Overview
13.1.18 Pacific Genetech Limited
Table 198 Pacific Genetech Limited: Business Overview
13.1.19 Riboxx GmbH
Table 199 Riboxx GmbH: Business Overview
13.1.20 Captivate Pharmaceuticals LLC
Table 200 Captivate Pharmaceuticals LLC: Business Overview
13.2 Other Players
13.2.1 Creative Diagnostics
13.2.2 Litevax B.V.
13.2.3 Mukta Industries
13.2.4 Oncovir, Inc.
13.2.5 Titermax Usa, Inc.
  • *Details on Business Overview, Products Offered, Recent Developments & Analyst's View Might Not be Captured in Case of Unlisted Companies.
14 Appendix
14.1 Discussion Guide
14.2 Knowledgestore: The Subscription Portal
14.3 Customization Options

Executive Summary

Companies Mentioned

  • Dynavax Technologies (US)
  • Croda International plc (UK)
  • GSK plc (UK)
  • Seppic (France)
  • Novavax (US)
  • SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
  • Agenus Inc. (US)
  • Phibro Animal Health Corporation (US)
  • Aurorium (Vertellus) (US)
  • Merck KGaA (Germany)
  • Vaxine Pty Ltd. (Australia)
  • Hawaii Biotech Inc. (US)
  • CSL Limited (Australia)
  • OZ Biosciences (US)
  • InvivoGen (US)
  • Allergy Therapeutics (UK)
  • EuBiologics Co., Ltd. (South Korea)
  • Pacific GeneTech Limited (US)
  • Riboxx GmbH (Germany)
  • CaPtivate Pharmaceuticals LLC (US)
  • Creative Diagnostics (US)
  • LiteVax BV (Netherlands)
  • Mukta Industries (India)
  • Oncovir, Inc. (US)
  • TiterMax USA, Inc. (US).

Methodology

Loading
LOADING...